Stepping up the Fight: Industry Collaboration to End HIV, Tuberculosis and Malaria
In this report, we have brought together highlights on how we are advancing our work in HIV, TB and malaria, with 14 exemplary case studies that illustrate some of our contributions to support the elimination of these diseases.
We have the opportunity to achieve the SDGs over the next 11 years, requiring increased collaborations across sectors — we invite all actors to explore our work and engage with us as we deepen the quality and impact of our programs
Related news and resources
How we are contributing to global pharmaceutical standards
The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future
This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
Lessons from regulatory agilities during the COVID-19 pandemic: views from members of National Regulatory Authorities
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read more